Beovu Lawsuit

Shortly after introducing the wet-age related macular degeneration (AMD) treatment Beovu, side effects were linked to reports of severe and potentially blinding vision problems. As a result, new warnings about this risk were added in June 2020.

STATUS OF BEOVU LAWSUITS: A limited group of users who received an injection for treatment of AMD between October 2019 and July 2020 may be entitled to financial compensation through a Beovu lawsuit.

Lawyers are reviewing cases for users who experienced:

• Retinal Vasculitis
• Retinal Vascular Occlusion
• Blurry Vision, Floaters or Other Complications

>>CONTACT A BEOVU LAWYER ABOUT A CASE<<

MANUFACTURER: Novartis

OVERVIEW: Beovu (brolucizumab) was approved by the FDA on October 7, 2019, as an injection treatment for wet age-related macular degeneration (AMD). It is part of a class of drugs known as anti-vascular endothelial growth factor therapy, or anti-VEGF. However, similar vision problems have not been linked to other medications in this class.

Within a few months after Beovu was introduced, eye specialists noted a number of concerning Beovu eye problems, involving serious inflammation of the vascular branches of the retinal artery, known as retinal vasculitis, which can result in symptoms like:

• Blurry Vision
• Visual Floaters
• Dark Spots in Vision
• Difficulty Distinguishing Colors
• Distorted Images

BEOVU VISION WARNINGS: In February 2020, the American Society of Retina Specialists (ASRS) issued warnings to its members about the link between Beovu and eye inflammation.

The group indicated that it was aware of at least 14 cases of retinal vasculitis following Beovu injections, including at least 11 cases that resulted in a retinal vascular occlusion, which occurs when the vein becomes blocked. This can cause a complete loss of vision and blindness if permanent damage is suffered by the retina.

On June 11, 2020, the FDA announced new Beovu warning label information, which highlights the risk of retinal vasculitis and retinal vascular occlusion following an injection. Doctors were urged to instruct patients to report any change in vision from Beovu without delay.

BEOVU LAWYERS REVIEWING CLAIMS: If earlier information had been provided to users about the potential Beovu side effects, many individuals who received the injection shortly after it was introduced may have avoided permanent vision problems.

Evidence suggests that Novartis knew or should have known about the vision risks associated with Beovu, yet placed its desire for profits before consumer safety by withholding important warnings that would have negatively impacted sales. As a result, Beovu lawyers are reviewing potential claims for individuals who received this injection prior to June 11, 2020 and experienced problems.